Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
주식 순위 #7143
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
주가
$40.39
마지막 동기화: 2023-08-18
시가총액
$1.70B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Chinook Therapeutics, Inc. (KDNY)

카테고리

Chinook Therapeutics, Inc. (KDNY)의 주식 분할 이력
Chinook Therapeutics, Inc. 주식 (심볼: KDNY)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 28, 2026에 발생했습니다.
Aug 28, 2026 이전에 매수한 KDNY 주식 1주는 현재 0주의 KDNY 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH